Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

May 15, 2021

POET: Oral Antibiotics Continue to Show Good Long-term Results for Endocarditis

News Conference News ACC 2019

POET: Oral Antibiotics Continue to Show Good Long-term Results for Endocarditis

March 18, 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

News Conference News ACC 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Yael L. Maxwell

March 17, 2019

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

March 21, 2017

Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)

Presentation ACC 2017

Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)

Presenter: Michael Mack

March 20, 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

News Conference News ACC 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

March 19, 2017

Live From Washington: ACC 2017, Day Three

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

March 19, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.